A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study)

The role of surgery in metastatic breast cancer

(2011) Jetske Ruiterkamp et al.   EUROPEAN JOURNAL OF CANCER

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

(2011) Michael Untch et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy

(2010) S. Guiu et al.   ANNALS OF ONCOLOGY

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

(2010) Gunter von Minckwitz et al.   BREAST CANCER RESEARCH AND TREATMENT

Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

(2010) Michael Untch et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

(2010) Luca Gianni et al.   LANCET

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

(2009) Kenichi Inoue et al.   BREAST CANCER RESEARCH AND TREATMENT

Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study

(2009) William M. Sikov et al.   JOURNAL OF CLINICAL ONCOLOGY

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine

(2009) J. S. Ross et al.   ONCOLOGIST

Cardiotoxicity Profile of Trastuzumab

(2008) Steven M Ewer et al.   DRUG SAFETY

Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial

(2008) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Locally Advanced and Inflammatory Breast Cancer

(2008) Stephen Chia et al.   JOURNAL OF CLINICAL ONCOLOGY